title: [The effect of captopril and valsartan on preventing the formation of atherosclerotic plaque].
abstract: OBJECTIVE
  To observe the effect of captopril and valsartan on preventing the formation of atherosclerosis plaque in rabbit atherosclerotic models.
  
  
  METHODS
  The atherosclerotic models of rabbits fed with high-cholesterol diet were used. There were four groups: high cholesterol group, high cholesterol + captopril group, high cholesterol + valsartan group, normal food group. The intima-media thickness in abdominal aortic were measured by ultrasound. The pathogenic features of the arterial walls were showed by HE stain and observed by light microscope.
  
  
  RESULTS
  There were less atherosclerotic plaque in high cholesterol + captopril group and high cholesterol + valsartan group than in cholesterol group. The intima-media thickness in high cholesterol + captopril group and in high cholesterol + valsartan group were much more decreased than in high cholesterol group (0.05 +/- 0.005, 0.05 +/- 0.007 vs 0.07 +/- 0.100, P < 0.01). The connection of the endothelial cells were less damaged in high cholesterol + captopril group and high cholesterol + valsartan group than in high cholesterol group.
  
  
  CONCLUSIONS
  Ti is true that angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) have the effect of preventing or decreasing the formation of atherosclerotic plaque in arterial wall. The findings suggest that ACEI and/or ARB should be first chosen for those with hypertension and with atherosclerotic risk factors or atherosclerotic diseases.
authors: Department of Cardiology, the Second Affiliated Hospital, Shanxi Medical University, Taiyuan 030001, China.
authors: Yu-sa
authors: YS
authors: Lu
authors: Xin-yu
authors: XY
authors: Lei
authors: Jie
authors: J
authors: DI
authors: Shu-tian
authors: ST
authors: Huang
authors: Jian-min
authors: JM
authors: Li
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001012:Aorta, Abdominal / Q000000981:diagnostic imaging / Q000473:pathology; D001161:Arteriosclerosis / Q000473:pathology / Q000517:prevention & control*; D002216:Captopril / Q000494:pharmacology*; D002791:Cholesterol, Dietary; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000473:pathology; D008297:Male; D011817:Rabbits; D013777:Tetrazoles / Q000494:pharmacology*; D014463:Ultrasonography; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000068756:Valsartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D002791:Cholesterol, Dietary; D013777:Tetrazoles; D000068756:Valsartan; D002216:Captopril; D014633:Valine